Biogen (BIIB) Stock Price, Quote, News & History | Benzinga

SPY778.61+0.01%QQQ751.25−0.00%BTC/USD82,371.70+0.83%DIA516.19+0.02%GLD384.57−0.00%TLT77.92−0.08%

Biogen Inc (BIIB) Stock Price, Quote, News & History

BIIBNASDAQ

Trade with Public

Trade with Public

$225.71

7.283.33%

Last update: Oct 9, 4:00 PM

$225.71

7.283.33%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$220.62

Close

-

Volume / Avg.

814.62K / 1.08M

Day Range

$219.23 - $227.20

52 Wk Range

138.00 - 230.49

Market Cap

$33.35B

P/E Ratio

38.80

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

4.39%

Days to Cover

7.59

Recent Biogen Inc. News

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.

Vandana Singh

Why Is Biogen Stock Falling Tuesday?

Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and a new weekly LEQEMBI FDA approval.

Vandana Singh

This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.

Avi Kapoor

Biogen: Key Takeaways From Needham’s Meeting With Top Management

Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key priorities. PT increased to $256.

Priya Nigam

Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

2.88B

Investing Cash Flow (TTM)

-5.32B

Financing Cash Flow (TTM)

985.00M

Free Cash Flow (TTM)

2.49B

Capital Expenditure (TTM)

-388.80M

Net Change in Cash (TTM)

-1.45B

Analyst Trends and Forecast

3

1

Jun

8

5

Jul

3

1

Aug

1

Sep

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$39.34B

PE Ratio (TTM)

38.80

PE Ratio (FWD)

13.40

PEG Ratio (TTM)

2.25

PS Ratio (TTM)

3.22

PB Ratio (TTM)

1.71

Earnings Yield % (TTM)

2.58%

Earnings Yield % (FWD)

7.46%

EV / EBITDA (TTM)

18.39

Price / EBITDA (TTM)

15.12

Price / Free Cash Flow (TTM)

12.99

Book Value / Share

$127.56

Company Debt

Total Debt

$8.09B

LT Debt

$7.29B

LT Debt Issuance (TTM)

$2.40B

LT Debt Repayment (TTM)

-$1.10B

Total Cash

$1.29B

Debt to Equity

0.44

Issuance of Debt (TTM)

$1.30B

Repayment of Debt (TTM)

-$1.10B